company background image
IF0 logo

InflaRx DB:IF0 Stock Report

Last Price

€1.84

Market Cap

€123.6m

7D

10.5%

1Y

44.3%

Updated

27 Nov, 2024

Data

Company Financials +

InflaRx N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for InflaRx
Historical stock prices
Current Share PriceUS$1.84
52 Week HighUS$2.25
52 Week LowUS$1.08
Beta1.58
11 Month Change32.09%
3 Month Change32.56%
1 Year Change44.34%
33 Year Change-56.29%
5 Year Change-40.00%
Change since IPO-85.60%

Recent News & Updates

Recent updates

Shareholder Returns

IF0DE BiotechsDE Market
7D10.5%-1.1%1.1%
1Y44.3%-18.8%7.2%

Return vs Industry: IF0 exceeded the German Biotechs industry which returned -18.3% over the past year.

Return vs Market: IF0 exceeded the German Market which returned 8.6% over the past year.

Price Volatility

Is IF0's price volatile compared to industry and market?
IF0 volatility
IF0 Average Weekly Movement20.4%
Biotechs Industry Average Movement6.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: IF0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: IF0's weekly volatility has increased from 15% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200762Niels Riedemannwww.inflarx.de

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

InflaRx N.V. Fundamentals Summary

How do InflaRx's earnings and revenue compare to its market cap?
IF0 fundamental statistics
Market cap€123.64m
Earnings (TTM)-€56.88m
Revenue (TTM)€168.50k

733.8x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IF0 income statement (TTM)
Revenue€168.50k
Cost of Revenue€773.27k
Gross Profit-€604.77k
Other Expenses€56.28m
Earnings-€56.88m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.97
Gross Margin-358.92%
Net Profit Margin-33,758.73%
Debt/Equity Ratio0%

How did IF0 perform over the long term?

See historical performance and comparison